The GOG-9929 Phase I trial (113), which tested this combination in 21 patients with node-positive, HPV-related cervical cancer, demonstrated significant T-cell population expansion and upregulation of activation markers, such as ICOS and PD-1, particularly enhancing HPV-specific T-cell responses in HPV18+ tumors. The gene discussed is ICOS; the disease is cervical carcinoma.